BIORAY PHARMACEUTICAL

BioRay is a commercial-stage biopharmaceutical company with a full suite of end-to-end capabilities in China, focusing on discovering, developing, manufacturing and commercializing medicines for immune-mediated diseases and cancer. As a pioneer in China’s biopharmaceutical industry, BioRay started the R&D of biological therapeutics in 2003 as a core business division of Hisun Pharmaceutical, a specialty comprehensive pharmaceutical group founded in 1956. In 2019, PAG, a leading Asia-focused p... rivate equity firm, acquired control of BioRay with an investment of RMB3.8B (USD$540M for 58% ownership), making it one of the largest PE investments in Asia’s biotechnology history. Currently, we have over 1,000 employees worldwide committed to delivering life-changing treatments for patients living with immune-mediated diseases and cancer. We operate three R&D and manufacturing centres in Taizhou and Hangzhou, China and San Diego, US, and have industry-leading commercial-scale manufacturing capacity, full-spectrum R&D capabilities from drug discovery to formulation, more than fifteen on-going clinical programs, and well-established nationwide commercial operations covering three marketed products in China.More